Human Alzehimer’s Disease Peripheral Blood Mononuclear Cells

Description

Human Alzheimer’s Disease Peripheral Blood Mononuclear Cells (AD PBMCs) are immune cells isolated from the peripheral blood of patients with Alzheimer’s disease (AD), primarily comprising lymphocytes (T cells, B cells, NK cells) and monocytes. AD is a progressive neurodegenerative disorder characterized by amyloid-beta plaques, neurofibrillary tangles (tau protein), and neuronal loss, leading to cognitive decline, memory impairment, and eventual dementia. AD PBMCs play a critical role in immune regulation and neuroinflammation. They often exhibit abnormal cytokine secretion (e.g., elevated TNF-α, IL-6), and altered T-cell responses, reflecting systemic immune dysfunction linked to AD pathogenesis. These cells are implicated in the peripheral inflammatory cascade that may exacerbate central nervous system pathology, including β-amyloid deposition and tau hyperphosphorylation. These AD PBMCs provide a platform for studying immune modulation in Alzheimer’s disease, evaluating immune response in Alzheimer’s disease, developing novel therapies involving PBMC Alzheimer’s, monitoring inflammation markers in Alzheimer’s disease, assessing adaptive immunity in Alzheimer’s disease, and performing comprehensive PBMC profiling Alzheimer’s disease.